Millions of people around the world are impacted by neurodegenerative diseases— the two most common are Alzheimer’s and Parkinson’s disease. Despite this high prevalence, there are currently only five drugs approved by the FDA to treat Alzheimer's disease. These medications do not treat the underlying causes of the disease or slow its progression. Now, with an increasingly aging population, there is a call to action among scientific experts to diversify neurodegenerative drug discovery through the exploration of new targets. Executives from companies that are each taking new approaches to treating neurodegenerative disorders will discuss their methodology and why they believe it is superior. Further discussion will center around the current challenges in neurodegenerative disease treatment, learnings from key failures and the anticipated next steps in global research. These issues are increasingly important in a global market projected to be worth more than $62B by the year 2026.